Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
Chiara Fabbri, Alessandro Serretti
Clinical Psychopharmacology and Neuroscience (2020) Vol. 18, Iss. 1, pp. 1-9
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis
Vincenzo Oliva, Matteo Lippi, Riccardo Paci, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2021) Vol. 109, pp. 110266-110266
Closed Access | Times Cited: 114
Adaptation of Lipid Profiling in Depression Disease and Treatment: A Critical Review
Bruno Pinto, Tiago Conde, Inês Domingues, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2032-2032
Open Access | Times Cited: 29
Precision psychiatry in clinical practice
Raffaella Zanardi, Dario Prestifilippo, Chiara Fabbri, et al.
International Journal of Psychiatry in Clinical Practice (2020) Vol. 25, Iss. 1, pp. 19-27
Closed Access | Times Cited: 41
Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
Sheng‐Min Wang, Nak-Young Kim, Hae-Ran Na, et al.
Clinical Psychopharmacology and Neuroscience (2021) Vol. 19, Iss. 2, pp. 341-354
Open Access | Times Cited: 37
Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial
John Papastergiou, Lena C. Quilty, Wilson Li, et al.
Clinical and Translational Science (2021) Vol. 14, Iss. 4, pp. 1359-1368
Open Access | Times Cited: 34
Polygenic dissection of treatment-resistant depression with proxy phenotypes in the UK Biobank
Ling-Hua Wang, Mei-Chiung Shih, Kuang Lin, et al.
Journal of Affective Disorders (2025)
Closed Access
Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response
Maike Scherf‐Clavel, Heike Weber, Catherina Wurst, et al.
Pharmacopsychiatry (2022) Vol. 55, Iss. 05, pp. 246-254
Open Access | Times Cited: 16
Short and long-term treatment outcomes of stepwise psychopharmacotherapy based on early clinical decision in patients with depressive disorders
Jae‐Min Kim, Robert Stewart, Hee‐Ju Kang, et al.
Journal of Affective Disorders (2020) Vol. 274, pp. 315-325
Closed Access | Times Cited: 24
Pharmacogenomics of drugs used to treat brain disorders
Ramón Cacabelos
Expert Review of Precision Medicine and Drug Development (2020) Vol. 5, Iss. 3, pp. 181-234
Closed Access | Times Cited: 20
Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic scores
Carolyn Riley Chapman
Journal of Community Genetics (2022) Vol. 14, Iss. 5, pp. 441-452
Open Access | Times Cited: 12
The role of pharmacogenetics in the treatment of major depressive disorder: a critical review
Sergio Barlati, Alessandra Minelli, Gabriele Nibbio, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 6
Comparison between Atomoxetine and OROS Methylphenidate as an Adjunctive to SSRIs in Attention-deficit/Hyperactivity Disorder Adults with Comorbid Partially Responsive Major Depressive Disorder: A Head-to-head, 12-week, Randomized, Rater-blinded Clinical Trial
Se-Hoon Shim, Young Sup Woo, Ji Sun Kim, et al.
Clinical Psychopharmacology and Neuroscience (2022) Vol. 20, Iss. 1, pp. 143-153
Open Access | Times Cited: 9
Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review
Alessandra Minelli, Sergio Barlati, Bernhard T. Baune
European Neuropsychopharmacology (2022) Vol. 59, pp. 68-81
Open Access | Times Cited: 8
Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response
Svenja Müller, Klaus Lieb, Fabian Streit, et al.
Journal of Affective Disorders (2024) Vol. 363, pp. 542-551
Open Access | Times Cited: 1
Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice
Kyung Ho Lee, Won‐Myong Bahk, Soo-Jung Lee, et al.
Clinical Psychopharmacology and Neuroscience (2020) Vol. 18, Iss. 4, pp. 621-626
Open Access | Times Cited: 9
Candidate genetic variants and antidepressant-related fall risk in middle-aged and older adults
A. C. Pronk, Lotta J. Seppälä, Katerina Trajanoska, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0266590-e0266590
Open Access | Times Cited: 5
Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial)
Alessandra Minelli, Sergio Barlati, Erika Vitali, et al.
Trials (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
Sungwon Roh, Kang Soo Lee, Songhwa Choi, et al.
Clinical Psychopharmacology and Neuroscience (2022) Vol. 20, Iss. 3, pp. 548-559
Open Access | Times Cited: 3
Positive psychology interventions in in-patients with depression: influences of comorbidity and subjective evaluation of the training programme
Antje Stemmler, Regina Staehle, Tina Heinemann, et al.
BJPsych Open (2021) Vol. 7, Iss. 4
Open Access | Times Cited: 4
Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 Study
Farhana Islam, Amanda Lisoway, Edward Oh, et al.
Pharmacopsychiatry (2024) Vol. 57, Iss. 05, pp. 232-244
Closed Access
Approche transdiagnostique des troubles psychiatriques résistants et complexes
A. Amad, M. Horn, Maeva Magnat, et al.
Encyclopédie médico-chirurgicale. Psychiatrie (2024) Vol. 40, Iss. 2, pp. 1-11
Closed Access
The relationship between familial-genetic risk and pharmacological treatment in a Swedish national sample of patients with major depression, bipolar disorder, and schizophrenia
Kenneth S. Kendler, Henrik Ohlsson, Jan Sundquist, et al.
Molecular Psychiatry (2023) Vol. 29, Iss. 3, pp. 742-749
Closed Access | Times Cited: 1
The Genetics of Major Depression: Perspectives on the State of Research and Opportunities for Precision Medicine
Roseann E. Peterson
Psychiatric Annals (2021) Vol. 51, Iss. 4, pp. 165-169
Open Access | Times Cited: 3
Ethical, Legal and Social Implications of Polygenic Scores for Multifactorial Disease: A Narrative Review Identifying Concerns About Interpretation and Use
Carolyn Riley Chapman
Research Square (Research Square) (2022)
Open Access | Times Cited: 1
Predictors of relapse following a stepwise psychopharmacotherapy regime in patients with depressive disorders
Jae‐Min Kim, Robert Stewart, Hee‐Ju Kang, et al.
Journal of Affective Disorders (2021) Vol. 293, pp. 109-116
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top